SLAMF7抗体;SLAMF7 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07221(SLAMF7 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P07221(SLAMF7 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The SLAMF7 (Signaling Lymphocyte Activation Molecule Family member 7) antibody is a therapeutic agent targeting the SLAMF7 receptor, a cell surface glycoprotein primarily expressed on immune cells, including natural killer (NK) cells, plasma cells, and certain T-cell subsets. SLAMF7. also known as CD319 or CS1. plays a critical role in regulating immune cell activation and adhesion. It mediates pro-survival signals in malignant plasma cells, making it a key target in multiple myeloma (MM) treatment.

Elotuzumab, the first FDA-approved SLAMF7 monoclonal antibody, exemplifies its clinical application. By binding to SLAMF7. elotuzumab exhibits dual mechanisms: directly targeting MM cells via SLAMF7 overexpression while enhancing NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). Unlike traditional monoclonal antibodies, it does not induce complement-dependent cytotoxicity (CDC) or direct apoptosis. Instead, it relies on immune modulation by activating NK cells through interactions with Fcγ receptors.

Clinical trials, such as the ELOQUENT-2 study, demonstrated improved progression-free survival when elotuzumab was combined with lenalidomide and dexamethasone in relapsed/refractory MM. Research also explores SLAMF7's broader role in autoimmune diseases and viral infections due to its involvement in lymphocyte signaling. Despite its success, resistance mechanisms and optimal combination strategies remain active areas of investigation. SLAMF7-targeted therapies highlight the growing importance of immunomodulatory antibodies in oncology.